Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 118

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 118
---
 and penalties), as well as expose us to criminal proceedings.
In addition, the IIA may from time to time conduct royalties audits and such audits may lead to additional royalties being payable on
additional products. Such grants may be terminated or reduced in the future, which would increase our costs. IIA approval is not required
for the marketing of products resulting from the IIA-funded research or development in the ordinary course of business.

In January 2018, we announced participation in a three-year IIA-sponsored
Phenomics Consortium to develop tools and systems for precision agriculture and innovative development of agriculture products. In addition
to Evogene, the Phenomics Consortium consists of several Israeli industrial companies and academic institutions. The goal of the consortium
is to develop plant phenotyping technologies, including the generation of comprehensive agricultural ‘ Big-Data’ and the development
of artificial intelligence algorithms for real time analysis of phenotypic data. The grant for the consortium was originally approved
for calendar year 2018 in an amount of approximately $5 million, of which approximately $1.4 million was granted to Evogene. By the end
of 2018, the grant was extended by an additional six months to a total period of 18 months until mid-2019, and the grant amount was updated
to approximately $7.6 million total, of which approximately $2.5 million was granted to Evogene. In June 2019, the IIA approved the continuation
of the consortium following such 18-month period, until the end of 2020, which would complete a three-year workplan, and granted an additional
amount of approximately $7.5 million, of which approximately $1.9 million was granted to Evogene.

72

In June 2020, we announced participation in a three-year workplan,
IIA-sponsored CRISPR-IL Consortium to develop an artificial intelligence based, end-to-end system for genome-editing to be used in multi-species
including human, plant, and certain animal DNA, applicable to market segments in pharma, agriculture and aquaculture. In addition to Evogene,
the CRISPR-IL Consortium consists of several Israeli industrial companies and academic institutions. The goal of the consortium is to
develop an artificial intelligence-based system, “ Go-Genome”, providing users improved genome-editing workflows. The system
aims to provide end-to-end solutions, from user interface to an accurate measurement tool. The total budget for the consortium was approved
for the first